Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170024/S024

Surpass Streamline Flow Diverter

Stryker Neurovascular · Decision date Aug 20, 2025

FDA DECISIONP170024/S024

What did the FDA decide?

FDA records P170024/S024 as a supplement to PMA P170024, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 20, 2025.

FDA approval order statement

approval for manufacturing process improvements for the manufacturing line for the Surpass Evolve Flow Diverter System (FDS) and Surpass Elite Flow Diverter System, as well as Stent Loader equipment upgrades for Surpass Evolve FDS.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Aug 20, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170024/S024
Regulatory pathway
PMA supplement
Product code
OUT
Decision code
OK30
Decision date
Aug 20, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intracranial aneurysm flow diverter.

Product code
OUT
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170024/S024 received

    Application receipt date recorded by FDA.

  2. P170024/S024 · FDA decision

    30-Day Notice

  3. P170024/S026 · Related supplement

    Surpass Evolve; Surpass Elite FDS

  4. P170024/S027 · Related supplement

    Surpass Elite Flow Diverter

Timeline entries are records held by MedtechLedger for P170024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170024

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker NeurovascularPMA supplementJun 26, 2026FDA
Stryker NeurovascularPMA supplementAug 28, 2026FDA

Explore the linked device profile

Other records with product code OUT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stryker Neurovascular

Headquarters
Not reported
Brand website
stryker.com
FDA applicant address
47900 Bayside Pkwy., Fremont, CA, 94538

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records